This site is archived and is no longer updated. It will be taken offline in mid-July. All the latest AWMSG recommendations, guidance and information is available on our new website at: https://awmsg.nhs.wales/.
awmsg logo



sirolimus (Rapamune®)


Reference No. 2707

Publication date:
04/12/2018


Appraisal information

sirolimus (Rapamune®) 1 mg/ml oral solution
sirolimus (Rapamune®) 0.5 mg tablet
sirolimus (Rapamune®) 1 mg tablet
sirolimus (Rapamune®) 2 mg tablet


Company: Pfizer Ltd
BNF category: Respiratory system
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
   
   
Submission Type: Nonsubmission
Status: Not endorsed
Advice No: Not available
Ratification by Welsh Government: 03/12/2018

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

This product is currently not marketed in the UK. In the absence of a submission from the holder of the marketing authorisation, sirolimus (Rapamune®) cannot be endorsed for use within NHS Wales for the treatment of patients with sporadic lymphangioleiomyomatosis with moderate lung disease or declining lung function
Statement of Advice (SOA)
Download